No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): has obtained the renewed Pharmaceutical production license.
Global Finance reported on February 18 that Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that the company received a new Pharmaceutical Production License issued by the Gansu Provincial Drug Administration on February 18, 2025, due to a change in the legal representative for the license renewal application.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): Elect Kang Yonghong as Director.
On January 10, Gelonghui reported that Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that the company's Board of Directors received written resignation reports today from Chairman Song Minping and Vice Chairman Zhu Kaicai. Mr. Song Minping applied to resign from his positions as a member of the fifth Board of Directors, Chairman, and committee member of the relevant specialized committees due to reaching the statutory retirement age (original term was from January 3, 2024, to January 2, 2027), and after resignation, he will no longer hold any positions in the company. Mr. Zhu Kaicai applied to resign from his position as Vice Chairman of the fifth Board of Directors due to work adjustments (original term was until May 16, 2024).
Gansu longshenrongfa pharmaceutical industry (300534.SZ): The subsidiary plans to purchase urea and other fertilizer products from related parties.
On December 6, Gelonghui reported that Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that, based on the needs of operation and business development, its wholly-owned subsidiary Gansu New Silkroutes Industry Investment Co., Ltd. (referred to as 'New Silkroutes') plans to purchase urea and other fertilizer products from the related party Gansu Yasheng Agriculture Comprehensive Service Co., Ltd. (referred to as 'Yasheng Agriculture'), with a purchase amount not exceeding 27 million yuan. Both parties intend to sign relevant trade agreements based on the actual situation.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): obtained a new pharmaceutical production license and passed the GMP inspection.
Galloon November 27th, gansu longshenrongfa pharmaceutical industry (300534.SZ) announced that the company recently obtained the "Pharmaceutical Production License" approved and reissued by the Gansu Provincial Drug Administration, as well as the issued "Pharmaceutical GMP Compliance Inspection Notification". The license is valid until April 12, 2026, license number: Gan 20160092. After the reconstruction of the traditional chinese medicine decoction pieces production line, it passed the pharmaceutical GMP compliance inspection and complies with the "Drug Production Quality Management Specification (Revised in 2010)", which is conducive to optimizing the company's production structure, promoting the production and sales of related products, better meeting market demand, and
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): does not involve drugs for nuclear pollution prevention.
On November 26, Gelonghui reported that gansu longshenrongfa pharmaceutical industry (300534.SZ) stated on the investor interaction platform that the company does not involve in drugs aimed at nuclear pollution prevention. Currently, the health food "Astragalus and Angelica Capsules" is made from gansu's authentic medicinal materials, the food-medicinal sources Astragalus and Angelica, based on an ancient famous prescription, which has clear effects in anti-radiation, replenishing qi and blood, and enhancing immunity. The formula of "Astragalus and Angelica Capsules" was created in response to market demand for health foods that improve radiation damage, primarily targeting people who work in radiation environments for extended periods, focusing on the function of improving radiation damage based on traditional Chinese medicine health theories.
Some Confidence Is Lacking In Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SZSE:300534) As Shares Slide 32%
